Insulin pump therapy. Subcutaneous insulin pump therapy (CSII) is currently the most physiological form of insulin delivery. Patients with type 1 diabetes can benefit from an improvement in HbA1c levels (HbA(1c): glycohemoglobin type A(1c)), a reduced rate of hypoglycemia, and reduced glucose fluctuations. Thereby improved glucose control can reduce the risk for long-term diabetic complications. Sensor-augmented pump therapy. CSII is the optimal basis to be used in combination with continuous glucose monitoring systems (CGM), the sensor-augmented pump therapy (SAP). This is a relevant first step towards a soon available closed-loop system, the artificial pancreas.